Acadia Pharmaceuticals | ACAD - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Cara Therapeutics USD -7.05M 1.11M 2026-03
Corcept Therapeutics USD 41.3M 90.9M 2026-06
Cytokinetics USD -179.17M 2.05M 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Incyte USD 700.4M 376.22M 2026-06
J&J USD 7.48B 860M 2026-06
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Pfizer USD 667M 4.32B 2026-06
Prothena USD 25.79M 53M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06